Skip to main content
SpringerLink
Log in

Chemotherapy and Novel Cancer Targeted Therapies

  • Chapter
  • First Online:
Book cover The Surgery of Childhood Tumors

  • 1404 Accesses

Abstract

Overall survival from childhood malignancies has dramatically improved, with survival rates now reaching over 70 %. Although improvements in radiotherapy and surgery have reduced the late sequelae of curative therapy, chemotherapy still remains the mainstay of treatment for most childhood cancers. Nevertheless, some types of childhood cancer remain a difficult challenge, and for those who survive the burden of late effects can be considerable. The current paradigm for new cancer therapies is to increase our knowledge of the molecular basis of carcinogenesis, followed by the development of cancer-cell specific therapies. During the past 10 years, initiatives have been undertaken by paediatric oncologists to further promote the clinical evaluation of new anti cancer compounds in children within national academic paediatric groups. Through proper evaluation in collaborative clinical trials we will learn how best to use these new therapeutic approaches and improve the survival rates and reduce toxicity for children with cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wallace WHB. Growth and endocrine function following the treatment of childhood malignant disease. In: Pinkerton CR, Plowman PN, et al., editors. Paediatric oncology: clinical practice and controversies. 2nd ed. London: Chapman and Hall Medical; 1997. p. 706–31. 29.

    Google Scholar 

  2. Bleyer WA. The impact of childhood cancer on the United States and the world. Cancer. 1990;40:355–67.

    CAS  Google Scholar 

  3. Lemerle J, Voûte PA, Tournade MF, et al. Effectiveness of preoperative chemotherapy in Wilms’ tumour: results of an international society of paediatric oncology (SIOP) clinical trial. J Clin Oncol. 1983;1(10):604–9.

    CAS  PubMed  Google Scholar 

  4. Voûte PA, Tournade MF, Delemarre JFM, et al. Preoperative chemotherapy as first treatment in children with Wilms’ tumour. Results of SIOP nephroblastoma trials and studies. SIOP proceedings, Abstract 123, Jerusalem; 1987.

    Google Scholar 

  5. Tournade MF, Com-Nougue C, Voute PA, Lemerle J, De Kraker J, et al. Results of the Sixth International Society of Pediatric Oncology Wilms’ Tumour Trial and Study: a risk-adapted therapy approach in Wilms’ tumour. J Clin Oncol. 1993;11:1014–23.

    CAS  PubMed  Google Scholar 

  6. Rickard KA, Loghman ES, Grosfeld JL, et al. Short and long-term effectiveness of enteral and parenteral nutrition in reversing or preventing protein energy malnutrition in advanced neuroblastoma; a prospective randomised study. Cancer. 1985;56:2881.

    Article  CAS  PubMed  Google Scholar 

  7. Rickard KA, Coates TD, Grosfeld JL, et al. The value of nutritional support in children with cancer. Cancer. 1986;48:1904.

    Article  Google Scholar 

  8. Capra S, Ferguson M, Ried K. Cancer: impact of nutrition intervention outcome – nutrition issues for patients. Nutrition. 2001;9:769–72.

    Article  Google Scholar 

  9. UKCCSG. Annual scientific report. United Kingdom Children’s Cancer Study Group; 2009.

    Google Scholar 

  10. Wyllie AH. Apoptosis. Br J Cancer. 1993;67:205–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Takimoto C, Page R. Principles of chemotherapy. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD, editors. Cancer management: a multidisciplinary approach, vol. 3. 5th ed. New York: Oncology Group; 1991. p. 21–38.

    Google Scholar 

  12. Lum BL, Fisher GA, Brophy NA, Yahanda AM, Alder KM, et al. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer. 1993;72(Suppl):3502–14.

    Article  CAS  PubMed  Google Scholar 

  13. Pinkerton CR, Hardy JR. Cancer chemotherapy and mechanisms of resistance. In: Pinkerton CR, Plowman PN, et al., editors. Paediatric oncology: clinical practice and controversies, vol. 6. 2nd ed. London: Chapman and Hall Medical; 1997. p. 159–88.

    Google Scholar 

  14. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727.

    CAS  PubMed  Google Scholar 

  15. Wallace WHB, Blacklay A, Eiser C, et al. Developing strategies for long term follow up of survivors of childhood cancer. Br Med J. 2001;323:271–4.

    Article  CAS  Google Scholar 

  16. Pritchard-Jones K, Pieters R, Reaman GH, et al. Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. Lancet Oncol. 2013;14(3):e95–103.

    Google Scholar 

  17. National Cancer Institute SEER Program. Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995. Bethesda: National Cancer Institute; 1999.

    Google Scholar 

  18. Coley W. The treatment of malignant tumours by repeated inoculation of Erysipelas: With a report of 10 original cases. Am J Med Sci. 1893;105:487–511.

    Article  Google Scholar 

  19. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.

    Article  CAS  PubMed  Google Scholar 

  20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–69.

    Article  CAS  PubMed  Google Scholar 

  21. Vassal G, Zwaan CM, Ashley D, Le Deley MC, Hargrave D, Blanc P, Adamson PC. New drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncol. 2013;14:e117–24.

    Article  PubMed  Google Scholar 

  22. Arceci RJ, Cripe TP. Emerging cancer-targeted therapies. Pediatr Clin North Am. 2002;49:1339–68.

    Article  PubMed  Google Scholar 

  23. Buchdunger E, Zimmermann J, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2- Phenylaminopyrimidine derivative. Cancer Res. 1996;56(1):100–4.

    CAS  PubMed  Google Scholar 

  24. Stegmeier F, Warmuth M, Sellers WR, Dorsch M. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther. 2010;87:543–52.

    Article  CAS  PubMed  Google Scholar 

  25. Adamson PC. Committee on shortening the time line for new cancer treatments. In: Adamson PC, Weiner SL, Simone JV, Gelband H, editors. Making better drugs for children with cancer. Washington DC: National Academies Press; 2005.

    Google Scholar 

  26. Kim SY, Toretsky JA, Scher D, Helman LJ. The role of IGF-1R in pediatric malignancies. Oncologist. 2009;14:83–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381:125–32.

    Article  CAS  PubMed  Google Scholar 

  28. Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of pre-defined specificity. Nature. 1975;256:495–7.

    Article  CAS  PubMed  Google Scholar 

  30. Lynch DA, Yang XT. Therapeutic potential of ABX- EGA: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 2002;29:47–50.

    Article  CAS  PubMed  Google Scholar 

  31. Waksal HW. Role of anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev. 1999;18(4):427–36.

    Article  CAS  PubMed  Google Scholar 

  32. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM, for the Children’s Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–34.

    Google Scholar 

  33. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, Berthold F. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer. 2011;11:21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Worth LL, Jeha SS, Kleinermann ES. Biologic response modifiers in pediatric cancer. Hematol Oncol Clin North Am. 2001;15:723–40.

    Article  CAS  PubMed  Google Scholar 

  35. Dillman R, Dselvan F, Schiltz D. Patient-specific dendritic cell vaccines for metastatic melanoma. N Engl J Med. 2006;355:1179–81.

    Article  CAS  PubMed  Google Scholar 

  36. Foster A, Rooney C. Improving T cell therapy for cancer. Expert Opin Biol Ther. 2006;6(3):215–29.

    Article  CAS  PubMed  Google Scholar 

  37. Suntharalingan G, Perry MR, Ward S, et al. Cytokineand storm in a Phase I trial of the anti-CD28 monoclonal antibody PDN1412. N Engl J Med. 2006;335:1018–28.

    Article  Google Scholar 

  38. Krause D, Van Etten RA. Tyrosine Kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–87.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Paediatric Oncology, Royal Hospital for Children, Glasgow, Scotland, UK

    Milind D. Ronghe

  2. Schiehallion Unit, Royal Hospital for Sick Children, Yorkhill, Glasgow, Scotland, UK

    Dermot Murphy

Authors
  1. Milind D. Ronghe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dermot Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Milind D. Ronghe .

Editor information

Editors and Affiliations

  1. Surgical Paediatrics, University of Glasgow, Glasgow, United Kingdom

    Robert Carachi

  2. Indianapolis, Indiana, USA

    Jay L. Grosfeld

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ronghe, M.D., Murphy, D. (2016). Chemotherapy and Novel Cancer Targeted Therapies. In: Carachi, R., Grosfeld, J. (eds) The Surgery of Childhood Tumors. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48590-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-48590-3_9

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-48588-0

  • Online ISBN: 978-3-662-48590-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation